📰 Cseries Program News
Page 2 - Cseries Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cseries Program. Real-time updates on events, politics, business and more.
January 17, 2024
EIR in Wetaskiwin is proud to announce a Three-Year Title Sponsorship with NAPA AUTO PARTS for the NASCAR Canada “Western Swing” Series.
October 18, 2023
In celebration of International Education Week this upcoming November, University Housing will hold the 17th annual Dance Around the World event at 6 p.m. on Tuesday, Nov. 15, in Holcombe Hall.
September 19, 2023
Greenbelt MD (SPX) Sep 15, 2023 - GOES-U, the fourth and final satellite in NOAAs GOES-R Series of advanced geostationary satellites, recently completed rigorous testing to ensure it can withstand the harsh conditions of launch and
September 15, 2023
Greenbelt MD (SPX) Sep 15, 2023 - GOES-U, the fourth and final satellite in NOAAs GOES-R Series of advanced geostationary satellites, recently completed rigorous testing to ensure it can withstand the harsh conditions of launch and
June 6, 2023
Halfwheel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from halfwheel.com Daily Mail and Mail on Sunday newspapers.
June 1, 2023
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing
May 30, 2023
Halfwheel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from halfwheel.com Daily Mail and Mail on Sunday newspapers.
April 26, 2023
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today the Journal of Clinical Oncology published...
April 25, 2023
WLRN News took home 14 wins and four finalist honors in the statewide Florida Association of Broadcast Journalists awards for journalism produced in 2022.
December 28, 2022
Domvanalimab-containing treatment regimens may improve outcomes, when compared with zimberelimab alone, in patients with PD-L1-high NSCLC.